Radiotherapy and hormone therapy after prostate surgery
Part of Cancer, Kidney & urinary clinical trials.
This study looks at combining radiotherapy and hormone therapy after prostate surgery to improve outcomes for men with prostate cancer. It uses samples and data from the larger RADICALS trial to understand which treatments work best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has not spread to other parts of the body.
- You have had surgery to remove your prostate (radical prostatectomy).
- Your PSA (prostate-specific antigen) level after surgery is lower than 0.4 ng/mL.
- You have not had a biochemical recurrence (a rise in PSA after surgery that signals the cancer may be back).
- You have not had hormone therapy or pelvic radiation before joining this trial.
- You have agreed to be part of the RADICALS study and provide samples for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
This trial studies giving hormone treatment and radiation before prostate surgery to treat high-risk, locally advanced prostate cancer. It aims to improve cancer control by shrinking or controlling the tumor before removing it.
This trial compares two ways of giving hormone therapy (apalutamide) along with radiation after prostate removal surgery. It aims to see which approach helps maintain quality of life while controlling cancer.
This Phase 3 trial compares two treatment approaches: stereotactic radiation therapy by itself versus the same radiation plus hormone therapy (ADT). It aims to see which plan works better for men with higher-risk prostate cancer without spread to lymph nodes or distant sites.
This trial studies whether giving a shorter-course radiation plan after prostate surgery, along with hormone shots (LHRH), can improve outcomes for people with higher-risk prostate cancer. You may be eligible if your PSA (a blood marker) is either still low but high-risk by pathology, or it has started to rise again after surgery.
This trial tests combining radiation therapy with two hormone-blocking drugs (darolutamide and degarelix) to treat intermediate-risk prostate cancer. The goal is to see if this combination is more effective and safe than radiation alone.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.